Share this article
Share this article
ResearchAndMarkets.com s offering.
The therapeutic market for T1D within the 8MM will grow from $4.9B in 2019 at a significant compound annual growth rate (CAGR) of 17.2% to $24B by 2029.
In particular, the publisher expects the US market will contribute the most to the T1D market s growth, contributing $4.3B sales in 2019 (87.7% of the T1D market) and $20.3B in 2029 (84.7% of the T1D market).
The launch of the first disease-modifying therapeutics will be the main drivers of growth over the forecast period, with the first preventative therapeutic for T1D, Teplizumab, expected to launch in the US during the forecast period. Other major drivers for the T1D market include the increased T1D diagnosed prevalence, and the uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs.